311 related articles for article (PubMed ID: 33978189)
1. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
[TBL] [Abstract][Full Text] [Related]
2. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
[TBL] [Abstract][Full Text] [Related]
3. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
[TBL] [Abstract][Full Text] [Related]
4. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
[TBL] [Abstract][Full Text] [Related]
5. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
6. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L; Stevenson K; Papaemmanuil E; Neuberg D; Bejar R; Boultwood J; Bowen DT; Campbell PJ; Ebert BL; Fenaux P; Haferlach T; Heuser M; Jansen JH; Komrokji RS; Maciejewski JP; Walter MJ; Fontenay M; Garcia-Manero G; Graubert TA; Karsan A; Meggendorfer M; Pellagatti A; Sallman DA; Savona MR; Sekeres MA; Steensma DP; Tauro S; Thol F; Vyas P; Van de Loosdrecht AA; Haase D; Tüchler H; Greenberg PL; Ogawa S; Hellstrom-Lindberg E; Cazzola M
Blood; 2020 Jul; 136(2):157-170. PubMed ID: 32347921
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
8. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
10.
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
[TBL] [Abstract][Full Text] [Related]
11. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
12. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
13. Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.
Song J; Hussaini M; Qin D; Zhang X; Shao H; Zhang L; Gajzer D; Basra P; Moscinski L; Zhang H
Am J Clin Pathol; 2020 Jun; 154(1):48-56. PubMed ID: 32112088
[TBL] [Abstract][Full Text] [Related]
14. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
Xiong B; Xue M; Yu Y; Wu S; Zuo X
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
[TBL] [Abstract][Full Text] [Related]
15. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
16. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
18. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
Gu S; Xia J; Tian Y; Zi J; Ge Z
BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
[TBL] [Abstract][Full Text] [Related]
19. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
[TBL] [Abstract][Full Text] [Related]
20. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]